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Abstract Ageing research benefits from the study of
accelerated ageing syndromes such as Hutchinson-
Gilford progeria syndrome (HGPS), characterized by
the early appearance of symptoms normally associated
with advanced age. Most HGPS cases are caused by a
mutation in the gene LMNA, which leads to the
synthesis of a truncated precursor of lamin A known
as progerin that lacks the target sequence for the
metallopotease FACE-1/ZMPSTE24 and remains con-
stitutively farnesylated. The use of Face-1/Zmpste24-
deficient mice allowed us to demonstrate that
accumulation of farnesylated prelamin A causes severe
abnormalities of the nuclear envelope, hyper-activa-
tion of p53 signalling, cellular senescence, stem cell
dysfunction and the development of a progeroid
phenotype. The reduction of prenylated prelamin
A levels in genetically modified mice leads to a
complete reversal of the progeroid phenotype,
suggesting that inhibition of protein farnesylation
could represent a therapeutic option for the treatment
of progeria. However, we found that both prelamin A
and its truncated form progerin can undergo either
farnesylation or geranylgeranylation, revealing the
need of targeting both activities for an efficient
treatment of HGPS. Using Face-1/Zmpste24-deficient
mice as model, we found that a combination of statins
and aminobisphosphonates inhibits both types of
modifications of prelamin A and progerin, improves
the ageing-like symptoms of these mice and extends
substantially their longevity, opening a new therapeu-
tic possibility for human progeroid syndromes
associated with nuclear-envelope defects. We discuss
here the use of this and other animal models to
investigate the molecular mechanisms underlying
accelerated ageing and to test strategies for its
treatment.
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Introduction
Ageing, the progressive and irreversible loss of
physiological integrity, is an extremely complex
process whose molecular basis remain incompletely
understood (Kirkwood 2005). Several human
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illnesses, known as segmental progeroid syndromes,
are characterized by the early development of multiple
biological alterations normally associated with
advanced age. Even though these rare and dramatic
conditions only partially recapitulate normal ageing,
their study has the potential of rendering valuable
information on the molecular mechanisms implicated
in the ageing process (Ramirez et al. 2007). Moreover,
the development of animal models that phenocopy
these syndromes can provide experimental sys-
tems useful to investigate the basis of particular
pathologies associated with ageing (atherosclerosis,
osteoporosis, osteoarthritis, cancer) and to perform
preclinical testing of therapeutic strategies against
these alterations.
Most human syndromes of accelerated ageing are
caused by one of two major mechanisms: defects in
DNA repair systems and alterations in the nuclear
lamina. The best understood progeroid syndrome
due to a DNA repair defect is Werner syndrome
(WS), also known as progeria of the adult.
WS patients show a wide array of symptoms of
premature ageing, which emerge at puberty and
include early growth stop, bilateral cataracts, grey
hair, scleroderma-like skin changes, subcutaneous
calcification, arteriosclerosis, diabetes mellitus, a
prematurely aged facies and a high incidence of
cancer. Most WS do not live past 50 years (Cox and
Faragher 2007). Typical cases of WS are caused by
null mutations in WRN, a gene coding for a protein
of the RecQ family with helicase and exonuclease
activities that plays important roles in homology-
dependent recombination repair and telomere main-
tenance (Yu et al. 1996). A Wrn-knockout mouse
model recapitulates the alterations observed in WS
patients at the molecular and cellular levels but,
strikingly, Wrn deficiency does not causes an
accelerated ageing phenotype in mice (Lombard
et al. 2000). In contrast, progeroid symptoms closely
recapitulating WS develop in double-mutant mice
lacking both Wrn and telomerase activity, revealing
the critical role of Wrn in telomere biology and its
relevance for the progeroid phenotypes caused by
WRN deficiency (Chang et al. 2004; Multani and
Chang 2007). These findings indicate that mice and
humans may show different sensitivity to progeroid-
causing alterations, and these differences have to be
carefully taken in consideration to interpret results
derived from the use of murine models.
Hutchinson-Gilford progeria syndrome (HGPS),
also known as progeria of childhood, is the best
known accelerated ageing syndrome caused by
defects of the nuclear envelope. HGPS is character-
ized by shortened lifespan, growth impairment,
sclerotic skin, early hair loss, aged-facies, decreased
joint mobility and cardiovascular problems (Henne-
kam 2006; Merideth et al. 2008; Pereira et al. 2008).
Most HGPS cases are caused by a silent mutation in
the LMNA gene, which encodes two components of
the nuclear envelope, the lamins A and C. Lamin A is
synthesized as a precursor known as prelamin A,
which undergoes a series of post-translational mod-
ifications including farnesylation, proteolytic removal
of the C-terminal tripeptide, carboxyl methylation of
the prenylated cysteine residue and finally, the
excision of the 15-residue farnesylated peptide. The
mutation present in HGPS patients activates a cryptic
splicing site, and leads to the synthesis of a prelamin
A isoform known as progerin or LAD50, which lacks
a 50-residue long fragment containing the tar-
get sequence for the final proteolytic step and
consequently remains constitutively farnesylated
(De Sandre-Giovannoli et al. 2003; Eriksson et al.
2003).
The use of genetically modified mice allowed us to
identify the zinc metalloprotease FACE-1 (also
known as ZMPSTE24) as the enzyme responsible
for the final proteolytic step during lamin A post-
translational maturation (Pendas et al. 2002). Accord-
ingly, Face-1/Zmpste24-deficient mice accumulate
farnesylated prelamin A at the nuclear envelope and
phenocopy human HGPS, providing a valuable
animal model for the study of this pathology (Pendas
et al. 2002; Bergo et al. 2002; Cadinanos et al. 2005;
de Carlos et al. 2008). Using transcriptional profiling
on tissues from this knockout model, we found that
hyperactivation of p53 signalling plays a key role in
the accelerated ageing phenotype, which is partially
reversed by p53 deficiency (Varela et al. 2005).
Moreover, the use of genetic approaches revealed that
lowering the prelamin A levels results in a total
rescue of this mouse model from the accelerated
ageing condition (Varela et al. 2005; Fong et al.
2004; 2006b). Based on this information, we have
performed preclinical studies to test anti-progeria
pharmacological approaches aimed to prevent the
accumulation of prenylated prelamin A isoforms
(Varela et al. 2008).
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Zmpste24-deficient mice as a model
of accelerated ageing
The zinc metalloprotease FACE-1/ZMPSTE24 is an
integral membrane protein highly conserved
throughout evolution that shows widespread expres-
sion in mammalian tissues (Freije et al. 1999; Tam
et al. 1998; Kumagai et al. 1999; Cadinanos et al.
2003). To investigate the biological roles of this
enzyme, we used gene targeting to generate Zmp-
ste24-/- mice (Pendas et al. 2002). Zmpste24-
deficient mice are apparently normal at birth, but
they show a striking accumulation of prelamin A at
the nuclear envelope, which leads to frequent
nuclear abnormalities at the cellular level. In turn,
these molecular and cellular alterations lead to the
development of severe age-related abnormalities at
the organismal level, including loss of subcutaneous
fat, reduced mobility due to skeletal and muscular
defects, hair loss and metabolic alterations (Pendas
et al. 2002; Bergo et al. 2002).
The subsequent identification of progerin as the
molecular cause of HGPS (De Sandre-Giovannoli
et al. 2003; Eriksson et al. 2003) revealed that a
proteolytic defect explains the resemblance of the
phenotype shown by Zmpste24-deficient mice to the
clinical features characteristic of HGPS. Thus,
whereas in Zmpste24-/- mice prenylated prelamin
A accumulates due to the absence of the protease
responsible for removing the C-terminal peptide that
contains the prenyl-cysteine residue, the accumula-
tion of progerin in HGPS is a consequence of the loss
of the Zmpste24 target site in this prelamin A
truncated isoform (Fig. 1). In addition, mutations in
ZMPSTE24 have also been found in several human
progeroid syndromes, such as mandibuloacral dys-
plasia (MAD) and restrictive dermopathy (RD)
(Agarwal et al. 2003; Navarro et al. 2005; Shackleton
et al. 2005; Sander et al. 2008), providing additional
support to the relevance of Zmpste24-/- mice as a
model for studying accelerated ageing. Interestingly,
accumulation of prenylated progerin has also been
associated with normal ageing, a finding that expands
considerably the interest of Zmpste24-deficient mice
and other related animal models of progeria (Scaffidi
and Misteli 2006).
Methylation
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Farnesylation
2nd cleavage
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Fig. 1 Lamin A and progerin processing. In Face-1/Zmp-
ste24-deficient mice, the absence of this metalloprotease causes
the accumulation of farnesylated prelamin A. In HGPS cells, a
C–T transition in the LMNA gene introduces a cryptic splicing
site, leading to the synthesis of an alternatively spliced mRNA
that encodes progerin, a truncated prelamin A variant that lacks
the Face-1/Zmpste24 target sequence and remains constitu-
tively farnesylated
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Transcriptional and biochemical alterations
in Zmpste242/2 progeroid mice
The accumulation of immature prenylated lamin forms
(prelamin A and progerin) at the nuclear envelope
produces severe alterations in its architecture, leading
to frequent nuclear blebbing and fragmentation (Pen-
das et al. 2002). These alterations in nuclear
architecture induced by prelamin A and progerin have
also been linked to a defective recruitment of DNA
repair factors and increased genomic instability (Liu
et al. 2005). In agreement with these findings,
transcriptional profiling of tissues from Zmpste24-
deficient mice revealed a clear up-regulation of p53
target genes, which becomes more pronounced as the
progeroid phenotype of these animals becomes more
dramatic (Varela et al. 2005). Upregulation of p53
pathway seems to underlie the reduced proliferative
capacity of adult Zmpste24-deficient fibroblasts and
play a causal role in the accelerated ageing phenotype
associated to prelamin A accumulation, as p53 defi-
ciency results in a delay of the accelerated ageing
process shown by Zmpste24-/- mice (Varela et al.
2005). The results derived from the use of this animal
model are, at least partially, translatable to human as
p53 activation has been detected in cells from RD and
HGPS patients (Liu et al. 2006). Moreover, it has been
reported that targeting progerin accumulation reverts
overexpression of p53 targets in aged individuals
(Scaffidi and Misteli 2006).
The persistence of ageing-related alterations in
Zmpste24-deficient mice lacking p53 reveals that
additional molecular mechanisms are involved in the
phenotype developed by these mice. Some of these
additional alterations seem to be part of a metabolic
pro-survival strategy turned into a pro-ageing mech-
anism due to its chronic activation. This is the case of
autophagy, the major lysosomal pathway for the
turnover of cytoplasmic components. In contrast to
the known decline of autophagy that results in the
accumulation of damaged macromolecules during
physiological ageing, progeroid mouse models exhibit
a pronounced activation of autophagic proteolysis
(Marino et al. 2008; Marino and Lopez-Otin 2008).
Remarkably, we found that this alteration is also
shared by other progeroid models which show alter-
ations in DNA repair systems. Increased autophagy in
Zmpste24-deficient mice is caused by a reduced
activity of mTOR, which, in turn, is linked to
activation of LKB1-AMPK signalling, transcriptional
changes in key genes for lipid and glucose metabolism
regulation, hypoglycemia and other alterations in
serum factors such as leptin, insulin and adiponectin
(Marino et al. 2008). These signalling alterations and
their associated metabolic changes have been related
to situations prolonging lifespan, such as calorie
restriction (Vijg and Campisi 2008), and could be
part of a response triggered by the nuclear abnormal-
ities present in Zmpste24-deficient animals. However,
the chronic activation of this pro-survival strategy can
result in a pro-ageing effect that contributes to the
progeroid phenotype of these mice (Marino et al.
2008). The apparently paradoxical activation of pro-
longevity mechanisms in Zmpste24-deficient proge-
roid mice confers this animal model a special interest
as a tool for investigating the potential undesirable
effects of nutritional and pharmacological anti-ageing
interventions and to develop complementary treat-
ments to mitigate them.
Altered stem-cell biology in Zmpste24-deficient
mice
The molecular alterations discussed in the previous
paragraphs could have a special relevance on the
accelerated ageing of Zmpste24-deficient organs and
tissues if these alterations affect the stem cells
responsible for their regenerative capacity. Physio-
logical ageing has been associated with changes in
the number and functionality of somatic stem cells
(Campisi 2005; Rando 2006). Thus, the availability
of Zmpste24-deficient mice allowed us to test the
hypothesis that stem cell dysfunction could be
similarly involved in accelerated ageing conditions.
Using in vivo labelling, we observed a significant
increase in the number of Zmpste24-deficient epider-
mal stem cells, accompanied by a reduction in their
proliferative potential and an increase in apoptosis in
their supporting cells (Espada et al. 2008). These
abnormalities are associated with defects in signal-
ling pathways such as Wnt-b-catenin, implicated in
the functional regulation of epidermal stem cells, and
microphtalmia transcription factor (Mitf), a master
regulator of melanocyte stem cells (Espada et al.
2008). Remarkably, an independent but highly com-
plementary study demonstrated in vitro that progerin
interferes with the biology of human mesenchymal
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stem cells (hMSCs) (Scaffidi and Misteli 2008),
revealing that the stem cell dysfunction identified in
the Zmpste24-deficient animal model also plays a role
in human progeria. Taken together, these results
suggest that the progeroid model of Zmpste24
protease deficiency could be used for in vivo testing
of cell-based anti-progeroid therapies.
Zmpste24-deficient mice as a model for
developing therapies against accelerated ageing
To investigate the role of unprocessed prelamin A in
accelerated ageing, we designed a breeding program
aimed at developing Zmpste24-deficient mice with
reduced levels of prelamin A. This approach revealed
that Zmpste24-/-Lmna?/- mice show significantly
reduced prelamin A levels and do not develop
progeroid symptoms, demonstrating the role of prel-
amin A accumulation as the primary cause of the
progeroid phenotype associated to Zmpste24 defi-
ciency (Varela et al. 2005; Fong et al. 2004). Parallel
studies carried out using HGPS fibroblasts showed
that accumulation of progerin plays an equivalent
causal role in the cellular phenotype developed by
these cells (Scaffidi and Misteli 2005). Moreover,
these studies pointed to the reduction of progerin
levels as an appropriate target to develop therapeutic
approaches against HGPS. Surprisingly, genetic abla-
tion of farnesyltransferase after birth does not lead to
an accelerated ageing phenotype in mice, even though
prenylation of prelamin A is a required step for its
subsequent proteolytic processing (Mijimolle et al.
2005). This observation suggested that the toxicity of
lamin A precursors depends on their prenylation
status and pointed to the use of farnesyltransferase
inhibitors (FTIs) as a potential treatment for these
conditions (Cadinanos et al. 2005). Thus, several
studies revealed that FTI treatment was capable of
improving the nuclear abnormalities in several cellu-
lar models of progeria (Glynn and Glover 2005;
Mallampalli et al. 2005; Yang et al. 2005; Toth et al.
2005; Capell et al. 2005).
Some in vivo benefit was also described in Zmp-
ste24-deficient mice (Fong et al. 2006a), although
further studies revealed that this treatment only
produced a marginal (5%) reduction in prelamin A
processing (Young et al. 2006). This low effectiveness
at the molecular level could be explained by an
alternative prenylation of prelamin A by geranylger-
anyltransferase type I under FTI treatment (Fig. 2), as
reported for other prenylated proteins such as K-Ras
(Whyte et al. 1997). To address this question, we tested
the effect of FTIs, alone or in combination with
geranylgeranyltransferase inhibitors (GGTIs), on
prelamin A processing in human cells. This approach
revealed a synergistic action of FTIs and GGTIs,
suggesting that prelamin A can be geranylgeranylated
in the setting of farnesyltransferase inhibition
(Varela et al. 2008). Furthermore, the use of mass
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Splicing
AS oligos
Small drugs
Isopentenyl-5-PP
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Fig. 2 Therapeutic options
to prevent the accumulation
of prenylated progerin. The
possibilities discussed
include compounds acting
on the mevalonate pathway
such as statins, and
aminobisphosphonates
(N-BPs), farnesyltransferase
inhibitors (FTI),
geranylgeranyltransferase
inhibitors (GGTI), and
agents designed to block the
alternative splicing event
that leads to progerin
synthesis such as small
drugs or specific antisense
oligonucleotides (AS
oligos)
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spectrometry analysis of prelamin A derived from
FTI-treated Zmpste24-deficient fibroblasts and prog-
erin derived from HGPS cells provided direct evidence
that these proteins are alternatively geranylgeranylated
when farnesylation is inhibited, which could explain
the low efficiency of FTIs in ameliorating the pheno-
types of progeroid mouse models. In agreement with
these findings, a combination of statins and amin-
obisphosphonates blocking several steps of the
farnesyl pyrophosphate and geranylgeranyl pyrophos-
phate biosynthetic pathway, efficiently inhibited both
farnesylation and geranylgeranylation of progerin and
prelamin A and improved the ageing-like phenotypes
of Zmpste24-deficient animals (Varela et al. 2008).
Based on these results, a clinical trial to test this
combination of drugs for the treatment of progeria has
been recently approved.
Additional animal models for studying
progeroid laminopathies
As discussed above, Zmpste24-deficient mice have
constituted a crucial tool to explore the mechanisms
underlying progeroid laminopathies and to design
therapeutic approaches for their treatment, whereas
other related animal models have confirmed or
extended these findings. Thus, the so-called ‘‘lamin C
only’’ mice, carrying a Lmna allele which fails to
undergo the lamin A-specific splicing, have revealed
that lamin A is dispensable in mice (Fong et al. 2006b).
These studies have also provided additional evidence
of the causative role of prelamin A accumulation in the
progeroid phenotype of Zmpste24-deficient animals,
thereby supporting the conclusions raised by using
Lmna?/- animals (Varela et al. 2005). Similarly,
knock-in mice carrying a ‘‘progerin-only’’ Lmna allele
phenocopy many of the abnormalities present in
Zmpste24-deficient animals, and show a modest ame-
lioration upon FTI treatment (Yang et al. 2005; 2006;
2008b). Even though a knock-in mouse expressing the
same mutant protein present in HGPS patients would
be expected to be the ideal model for this disease, the
reported ‘‘progerin-only’’ mice present some prob-
lems. First, the maintenance of the model has to rely on
chimeras due to the fertility problems of the mice
heterozygous for this mutation, making very difficult to
generate enough animals to reach statistical signifi-
cance in any study. Second, the expression levels of
progerin and the ratio progerin/normal lamins A/C are
different to those observed in HGPS patients. Third, the
genomic sequences involved in the alternative splicing
responsible for HGPS are absent in the ‘‘progerin-
only’’ allele, precluding the use of this model to test
therapeutic approaches such as specific oligonucleo-
tides or small drugs designed to target this pathogenic
splicing event (Fig. 2) (Scaffidi and Misteli 2005).
Remarkably, the recent information derived from
two new Lmna knock-in models has validated
important aspects of previous work with Zmpste24-
deficient mice. Thus, Yang et al. have reported that
mice with a Lmna allele encoding a non-prenylatable
progerin (nHG) show substantially milder abnormal-
ities and an extended longevity as compared to mice
with a prenylatable ‘‘progerin-only’’ allele (Yang
et al. 2008a). The amelioration observed in these
mice is comparable to that obtained in Zmpste24-
deficient animals treated with a combination of
statins and aminobisphosphonates capable of block-
ing efficiently prelamin A prenylation (Varela et al.
2008). Moreover, this study has revealed that accu-
mulation of non-prenylated progerin also causes
accelerated ageing symptoms, suggesting that thera-
peutic approaches based on blocking progerin
prenylation may require complementary interventions
to reach a complete efficacy (Yang et al. 2008a).
Finally, Davies et al., have described a Lmna knock-
in allele encoding a geranylgeranylated progerin that
also causes a progeroid phenotype, providing a
formal demonstration of the toxicity of this alterna-
tively modified protein (Davies et al. 2008), and
supporting the conclusions derived from mass spec-
trometry analysis of FTI-treated Zmpste24-deficient
and HGPS cells (Varela et al. 2008).
Besides the knock-in mice discussed above, several
transgenic models of progeria have also been devel-
oped. Thus, Varga et al. (2006) have developed a
transgenic mouse strain carrying a 164-kb bacterial
artificial chromosome containing an LMNA allele with
the HGPS point mutation. These transgenic mice suffer
important vascular alterations, which constitute the
most common cause of death for HGPS patients, but
they do not show any other progeroid phenotype,
limiting their utility as a model of accelerated ageing.
The epidermal alterations characteristic of progeroid
laminopathies have prompted other authors to develop
transgenic models expressing progerin in keratino-
cytes. Thus, mice expressing FLAG-tagged human
12 Transgenic Res (2009) 18:7–15
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progerin under the control of a keratin 14 promoter
have abnormal morphology of keratinocyte nuclei, but
they do not show any skin pathology (Wang et al.
2008). In contrast, doxycycline-regulated transgenic
mice (tet-off) expressing human progerin under a
keratin 5 promoter develop dental and skin alterations
which are reversed upon suppression of the transgene
expression (Sagelius et al. 2008a; b). The reasons for
the apparent discrepancies between these two works
are currently unclear, and can be related to subtle
differences in the spatio-temporal pattern of expression
of the transgene in both systems.
Future models and perspectives
As discussed above, several knock-out, knock-in and
transgenic animal models have been used to inves-
tigate the role of alterations in the prelamin A post-
translational maturation in accelerated ageing and to
develop therapeutic strategies against progeroid
symptoms. All these models have provided valuable
information on the biological relevance of prelamin
A maturation. However, important questions remain
to be answered, concerning aspects such as the
relative contribution to the progeroid phenotype of
cell-autonomous versus systemic alterations. The
investigation of this important aspect will be facili-
tated by the use of inducible systems, similar to the
tet-off system used to direct progerin expression to
keratinocytes, but designed to express prelamin A or
progerin in other organs and tissues with a decisive
role in the clinical manifestations of accelerated and
physiological ageing. New animal models are also
required to test in vivo anti-progeria therapies, since
none of the currently available mice are appropriate
to test approaches such as those targeting the
alternative splicing responsible for progerin produc-
tion. Lmna knock-in mice carrying an allele with the
complete genomic sequence involved in this splicing
event will probably be the ideal model to investigate
this type of interventions. Finally, animal models will
predictably play a key role as tools for investigating
not only the implications of the Zmpste24/lamin A
system in accelerated and physiological ageing, but
also in other important processes such as cancer. In
this regard, recent work illustrates the relevance of
this system in cancer and supports its interest as
target of anti-cancer therapies (Willis et al. 2008), an
aspect that will be the subject of future studies based
on the use of currently available and newly developed
animal models. In summary, the use of genetically
modified mice has allowed investigating the molec-
ular mechanisms underlying progeroid laminopathies
and has lead, in a very short period of time, to clinical
trials for testing rationally designed treatments
against these dramatic diseases. Nevertheless, impor-
tant aspects remain unsolved that will require further
investigations based on currently available and newly
developed animal models.
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